×
DaVita Receivables 2010-2024 | DVA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
DaVita receivables for the quarter ending September 30, 2024 were
$2.631B
, a
10.66% increase
year-over-year.
DaVita receivables for 2023 were
$2.416B
, a
5.28% decline
from 2022.
DaVita receivables for 2022 were
$2.551B
, a
5.81% increase
from 2021.
DaVita receivables for 2021 were
$2.411B
, a
1.16% decline
from 2020.
View More
DaVita Receivables 2010-2024 | DVA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
DaVita receivables for 2023 were
$2.416B
, a
5.28% decline
from 2022.
DaVita receivables for 2022 were
$2.551B
, a
5.81% increase
from 2021.
DaVita receivables for 2021 were
$2.411B
, a
1.16% decline
from 2020.
Related Stocks
Company Name
Market
Cap
Fresenius SE (FSNUY)
$20.4B
Quest Diagnostics (DGX)
$17.8B
Encompass Health (EHC)
$10.4B
Chemed (CHE)
$8.4B
Elanco Animal Health (ELAN)
$7B
RadNet (RDNT)
$5.4B
Option Care Health (OPCH)
$3.8B
Amedisys (AMED)
$3.2B
LifeStance Health (LFST)
$2.8B
Addus HomeCare (ADUS)
$2.3B
Astrana Health (ASTH)
$2.3B
U.S Physical Therapy (USPH)
$1.4B
Pennant (PNTG)
$1.1B
Aveanna Healthcare Holdings (AVAH)
$1.1B
Atai Life Sciences (ATAI)
$237M
Daxor (DXR)
$46M
MEDIROM Healthcare Technologies (MRM)
$14M
Psychemedics (PMD)
$14M
ATI Physical Therapy (ATIP)
$11M
Ontrak (OTRK)
$8M
IMAC Holdings (BACK)
$1M